Advancing cancer research - celebrating GenesisCare's pioneering research and clinical advancements over the past year.
GenesisCare Annual Research Report 2025
Contents
0 4
Introduction
06
Key stakeholders
14
Research in numbers
16
Research locations
18
Medical oncology
19
Radiation oncology
20
Theranostics
21
Haematology
22
Benign - DEPART trial
24
MR-Linac program
26
Quality
28
Partnerships
30
Sponsorships and events
32
JT’s Journey: A Life-Saving Experience
33
All in a Day’s Work: Amber’s Story
34
Helping clinicians bring research ideas to life
36
Publications, awards and media
38
Publications for 2025
2
Introduction Cancer remains Australia’s leading cause of disease burden. 1 As the largest private provider of cancer care in Australia, GenesisCare has both a responsibility and the privilege to contribute to improved outcomes for patients. Research and clinical trials are embedded across the majority of its 52 clinics nationwide, positioning GenesisCare as a key contributor to treatment innovation and the acceleration of cancer outcomes. Biomarker-driven oncology now underpins modern cancer care. Almost half of all oncology clinical trials incorporate biomarkers, reflecting a shift from traditional organ-based treatment approaches toward molecularly targeted therapies. Increasingly, trials assess multiple biomarkers simultaneously - including pan- tumour markers - allowing treatment decisions to be guided by tumour biology rather than anatomical site alone. This evolution is reflected at GenesisCare, where more than 80% of coordinated oncology clinical trials now involve molecularly targeted therapies , aligning with the organisation’s patient-centred approach to care. Advances in precision radiation therapy are also expanding the role of radiation oncology
Ongoing focus on biomarker-driven trials, data integration, workforce capability, and scalable research infrastructure will be critical to maintaining Australia’s global standing in cancer innovation while delivering meaningful benefits for patients. Across the GenesisCare network in 2025, there were 163 active unique research projects , increasing to 217 nationally when multi-site studies are included. These encompassed interventional trials and observational research across medical oncology, haematology, radiation oncology, and theranostics. In parallel, GenesisCare contributed to more than 80 external research initiatives and clinical quality registries and produced 62 peer-reviewed publications . Collectively, these activities demonstrate a balanced and strategic investment in therapeutic innovation, outcomes research, and real-world evidence generation. Through this work, GenesisCare clinicians and research teams continue to achieve national and international recognition for excellence in clinical research, innovation, and academic leadership - reinforcing the organisation’s role in delivering evidence-based, patient-centred cancer care.
beyond malignant disease. In selected benign conditions, high-precision, low-dose radiation can offer durable symptom control with minimal risk. 4-9 Contemporary applications include benign brain tumours, functional disorders, vascular abnormalities, and emerging indications in degenerative and inflammatory musculoskeletal conditions. This broadened scope reflects the evolution of radiation oncology from a tumour-focused discipline to one that applies precision radiation science to support patient-centred outcomes across a wider spectrum of disease. GenesisCare continues to leverage advanced technologies such as stereotactic radiosurgery and image-guided radiation therapy to improve tumour control while minimising toxicity. 2,3 These technologies are increasingly integrated with systemic therapies and precision-led clinical trials. Sustained investment in precision oncology aligns with both GenesisCare’s strategic priorities and the objectives of the Australian Cancer Plan, developed by Cancer Australia, which emphasises personalised care, equity of access, and improved outcomes.
Dr Marcus Dreosti BSc, Hons LLB, MBBS (Hons) FRANZCR Chief Medical Officer Radiation Oncologist
Sonya McColl BHlthSc (Nursing), RN, AdvDip (Management) Head of Research GenesisCare Australia
4
5
Key stakeholders 2025 principal investigators
Radiation oncology
Dr Marcus Dreosti Clinical interests include breast, prostate, gastrointestinal and gynaecological.
Dr Marie Burke OAM Clinical interests in breast, gynaecological, and skin cancers.
Prof Jarad Martin Clinical interest in prostate, bladder, rectal, anal, gastrointestinal cancers, and benign conditions (including Dupuytren’s disease and Ledderhose disease).
A/Prof Yvonne Zissiadis
Dr Jeremy de Leon Clinical interests in upper gastrointestinal, urogenital, lung cancers and advanced treatment technology including MR-Linac.
A/Prof Peter Graham Clinical interests in breast cancer, lung
Prof John Leung Clinical interests in all
Dr Gerry Adams Clinical interests in head and neck cancers, skin malignancies, central nervous system (CNS) and general oncology.
Clinical interests in breast cancer, gastrointestinal
areas of radiation oncology including urological, lung, gastrointestinal (GI), sarcoma, and central nervous system (CNS) plus lymphoma and palliative radiation therapy.
cancers, and haematology.
cancer, head and neck cancer, plus skin cancer.
A/Prof Michael Ng Clinical interests in prostate, breast, lung, and gastrointestinal cancers, lymphoma and stereotactic radiation therapy.
Dr James MacKean Clinical interests in breast cancer, melanoma, liver malignancies, and upper gastrointestinal malignancies.
Prof Michael Chao Clinical interests in breast, lung, and prostate cancers.
Dr Bradley Wong Clinical interests in skin cancer, prostate cancer, urological cancers, breast cancer, palliative care, and benign conditions.
Dr David Schlect Clinical interests in neurological, brain and spine, lung, and skin cancers, sarcoma, benign conditions (including Dupytren’s disease, keloid scars), and rare tumours.
Prof David Christie Clinical interests in urological (including prostate) cancers, and skin cancers plus benign conditions.
Dr Nina Stewart Clinical interests in breast cancer, neuro- oncology, and palliative radiation therapy.
Prof Bryan Burmeister Clinical interests in
gastrointestinal, skin, lung, head and neck, sarcoma, and oesophageal malignancies, general oncology, and clinical research.
6
7
Key stakeholders 2025 principal investigators
Radiation oncology
Dr Sandy Sampaio Clinical interests in brain & spine cancer, gastrointestinal cancer and palliative cancer.
Dr Mario Guerrieri Clinical interests in urological, breast, lung, prostate and gastrointestinal malignancies.
Dr Philippa Ell Clinical interest in hepatobiliary, breast, lung, upper gastrointestinal (GI), and stereotactic radiation therapy.
Dr Anne Capp Clinical interests in genitourinary, colorectal and gynaecological cancers, haematological malignancies and palliative care.
Dr Phuong Tran Clinical interests in
Dr Andrew Potter Clinical interests in breast, lung, skin, urological, gynaecological, haematological, prostate,
Dr Rodrigo Diaz Clinical interests in breast, skin, central nervous system (CNS), and haematological malignancies, plus general palliative radiation therapy.
Dr Sagar Ramani Clinical interests in genitourinary, lung, breast, colorectal and gastrointestinal cancers.
breast cancer, urological including prostate cancer, lung malignancies, and palliative care.
and central nervous system cancers, plus palliative care.
Dr George Papadatos Clinical interest in breast, skin, central nervous system (CNS), and haematological malignancies, plus general palliative care.
A/Prof Gillian Lamoury Clinical interests in breast cancer, sarcoma, palliative oncology, and benign diseases.
A/Prof Tee Lim Clinical interests in breast, urological, gastrointestinal, and lung cancers.
A/Prof Tim Wang Clinical interests in breast cancer, melanoma, liver malignancies, and upper gastrointestinal malignancies.
Dr Gina Hesselberg Clinical interests in breast cancer, upper gastrointestinal cancer, liver cancer, neuroendocrine tumours, and palliative care.
Dr Serena Sia Clinical interests in
Dr Katherine Neville Clinical interests in breast, skin, and lung cancers, palliative care radiation therapy, and haematology
Dr Eric Wegener Clinical interests in prostate cancer, skin cancer, brain and spine cancers, gastrointestinal cancer, genitourinary cancer, and lung cancer.
A/Prof Sid Baxi Clinical interests in skin, head and neck, thoracic, blood, liver, brain, breast, and gastrointestinal cancers.
brain, spine and upper gastrointestinal tumours, plus skin cancer, genitourinary cancer and benign conditions.
8
9
Key stakeholders 2025 principal investigators
Radiation oncology
Medical oncology
Dr Tulasi Ramanarasiah
Dr Matt Mason Clinical interests in head and neck cancer, breast cancer, skin cancer, prostate cancer, and palliative care.
Dr Art Kaminski Clinical interests in lung, liver, bone, brain, spine, and skin cancers.
Dr Hendrick Tan Clinical interests in neuro- oncology (brain, skull base, spine), SABR/SRS, MRIgRT adaptive RT, thoracic, oligometastases, upper gastrointestinal, skin and urological cancers.
Prof Nick Pavlakis Clinical interest in lung and gastrointestinal cancers, mesothelioma and neuroendocrine tumours.
Dr Sally Barron Hay
Dr Laurence Krieger Clinical interests in prostate, bladder, kidney, and testicular cancers.
A/Prof Connie Diakos Clinical interests in breast, gastrointestinal, neuroendocrine tumours, and gynaecological cancers.
Prof Stephen Clarke Clinical interests in thoracic and gastrointestinal cancers including neuroendocrine tumours and mesothelioma.
Clinical interests in breast cancer, gynaecological cancer, skin cancer and palliative radiation therapy.
Clinical interests in breast cancer and gynaecological malignancies.
Dr Mark Sidhom Clinical interest in genitourinary cancers (including prostate, bladder and kidney cancer).
Dr Esther Sim Clinical interests in breast, lung, neurological, skin cancers and general oncology.
Dr Joshua Sappiatzer Clinical interests in breast cancer, lung cancer, urological cancers, gastrointestinal cancers, central nervous system tumours, head and neck cancers, and skin malignancies, plus benign conditions such as Dupuytren’s contracture.
Prof Angela Hong Clinical interests in
A/Prof Nick Murray Clinical interests in breast and gynaecological cancers.
Dr Ayesha Salim Clinical interests in melanoma, autologous T-cells and theranostics clinical trials.
Dr Mark Macgregor Clinical interests in gastrointestinal, genitourinary, breast and lung cancers.
Dr Vy Broadbridge Clinical interests in lung, gynaecological, melanoma, gastrointestinal and breast cancers.
Dr Adrian Lee Clinical interest in genitourinary, brain, plus head and neck cancers.
melanoma, skin, sarcoma, lymphoma and neurological cancers.
10
11
Key stakeholders 2025 principal investigators
Medical oncology
Haematology
Dr Colin Chen Clinical interest in prostate and gynaecological.
A/Prof Deme Karikios Clinical interest in lung and gastrointestinal (GI) cancers.
Dr Alex Davis Clinical interests in horacic malignancies and clinical trials.
Dr David Kliman Clinical interest in lymphoma, myeloma, leukaemia, cellular therapies, thrombosis and general haematology.
Dr Wilfrid Jaksic Clinical interests in lymphoma and general haematology.
Dr Anya Hotinski Clinical interest in general haematology.
A/Prof Ian Lewis Clinical interests include lymphoma, myelodysplastic and myeloproliferative disorders as well as general haematology.
Dr David Chan Clinical interest in gastrointestinal, genitourinary and neuroendocrine cancers.
Theranostics
Dr Tony Michele Clinical interest in prostate cancer, brain tumours and melanoma.
A/Prof John Park Clinical interests in genitourinary, lung, breast, colorectal and gastrointestinal cancers.
A/Prof Stephanie Lim Clinical interests in Gastrointestinal oncology, translational research.
Dr Felicia Roncolato
Dr Jessica Smith Clinical interests in skin, lung and non-melanoma skin cancers.
Clinical interests in medical oncology – genitourinary, gynaecological and breast cancers.
Dr Aviral Singh Clinical interests in Theranostics.
A/Prof Joe Cardaci Clinical interests in prostate cancer and neuroendocrine tumours.
A/Prof Dinesh Sivaratnam Clinical interests in metastatic prostate cancer.
12
13
Research in numbers - 2025 217 Active research projects 140 Interventional 23 Prospective observational 54 Retrospective observational
Phase IV (1%)
Theranostics (10%)
Haematology (4%)
Phase 0 (2%)
83
Observ. (14%)
Radiation oncology (19%)
Phase III (38%)
External sponsors
Medical oncology (65%)
Phase I (32%)
4,068
Total patients participating in research
71
Phase II (13%)
2,027
2,041
Principal Investigators
Patients in observational studies
Patients in interventional studies
Total active studies by subspeciality
Total active studies by phase
58
31
26 20
GenesisCare investigator initiated trials (8%)
Prostate
Breast
Basket
Observational (14%)
External research projects contributing real-world data
Top disease sites
44 52
62
Collaborative (25%)
Number of research sites
Dedictated research staff FTE
Industry (67%)
Published articles
Interventional (86%)
43
8
Studies activated
Total active studies by sponsor type
Total active studies by project type
9
34
Grant applications
Running at multiple GenesisCare sites
Single sites
14
15
Research locations
WA
NSW
Bunbury (RO, Ph II – Ph IV, O)
1.
Newcastle (RO, Ph II – Ph IV, O) North Sydney (RO, Ph II – Ph IV, O) Darlinghurst (RO, Ph II – Ph IV, O)
24.
Fiona Stanley Hospital (RO, Ph II – Ph IV, O)
2.
25.
Wembley (RO, Ph II – Ph IV, O) Joondalup (RO, Ph II – Ph IV, O)
3.
26.
4.
Hurstville (RO, MO, HAEM, Ph II – Ph IV, O) Frenchs Forest (RO, MO, HAEM, Ph II – Ph IV, O) St Leonards (RO, MO, THA, HAEM, Ph I – Ph IV, O)
27.
Greenfields (RO, MO, Ph II – Ph IV, O) Nedlands (RO, THA, Ph II – Ph IV, O) Murdoch (RO, THA, Ph I – Ph IV, O)
5.
28.
6.
29.
7.
Kingswood (RO, MO, Ph I – Ph IV, O)
30.
Spender Park (RO, O)
8.
15
Maitland (RO, MO, THA, Ph II – Ph IV, O)
31.
16
18
SA
17
Bella Vista (RO, O)
32.
19
Kurralta Park (RO, Ph II – Ph IV, O)
9.
22
20
Campbelltown (RO, MO, HAEM, Ph I – Ph IV, O)
33.
St Andrew’s Precinct (RO, THA, HAEM, MO, Ph I – Ph IV, O)
26
10.
23
21
Macquarie Park (RO, Ph II - Ph IV, O)
Bedford Park (RO, Ph II – Ph IV, O)
34.
11.
4
North Adelaide (MO, HAEM, Ph I– Ph IV, O) Elizabeth Vale (MO, RO, Ph II – Ph IV, O) Henley Beach (MO, HAEM, Ph I– Ph IV, O)
3
12.
24
31
VIC
6
32
2
Epping (RO, Ph II – Ph IV, O) Footscray (RO, Ph II – Ph IV, O) Frankston (RO, Ph II – Ph IV, O) Fitzroy (RO, Ph II – Ph IV, O)
28
13.
5
34
35.
25
30
14
33
7
13
1
28
27
10
8
14.
9
36.
26
42
12
11
43
37.
QLD
35
38 41
36
Rockhampton (RO, O)
15.
38.
39
40
37
44
Bundaberg (RO, MO, Ph II – Ph IV, O) Fraser Coast (RO, MO, Ph II – Ph IV, O)
16.
Malvern (RO, MO, THA, Ph I – Ph IV, O)
39.
17.
Berwick (RO, Ph II – Ph IV, O) Ringwood (RO, Ph II – Ph IV, O) Albury Wodonga (RO, Ph II – Ph IV, O)
40.
Noosa (RO, O)
18.
41.
National quick look
Buderim (RO, O)
19.
All sites except North Adelaide North Shore, Frenchs Forest, Kingswood, Hurstville, Maitland, Campbelltown, Bundaberg, Hervey Bay, St Andrews Precinct, North Adelaide, Playford, Cabrini, Mandurah, Bunbury, Wembley North Shore, Maitland, Tugun, St Andrew’s Precinct, Cabrini, Murdoch, Hollywood North Shore, Frenchs Forest, Hurstville, St Andrew’s Precinct, North Adelaide, Campbelltown RO MO THA HAEM
42.
Chermside (RO, Ph II – Ph IV, O)
20.
Shepparton (RO, Ph II – Ph IV, O)
43.
Legend
Wesley Medical Centre (RO, Ph II – Ph IV, O)
21.
RO = Radiation Oncology MO = Medical Oncology THA = Theranostics HAEM = Haemotology Phase I = Ph I
Phase II = Ph II Phase III = Ph III Phase IV = Ph IV O = Observational
Peninsula Private Hospital (RO, Ph II - Ph IV, O)
44.
Southport (RO, Ph II – Ph IV, O)
22.
Tugun (RO, THA, Ph II – Ph IV, O)
23.
16
17
Medical oncology
Radiation oncology
breast cancer could safely omit radiation therapy following breast-conserving surgery and endocrine treatment. The trial enrolled 1,176 participants overall, with GenesisCare contributing an impressive 12% patients across multiple sites. The study closely aligns with our focus on personalised, evidence-based care. Many participants reported valuing the opportunity to contribute to research that may shape future treatment pathways, as well as the reassurance provided by close clinical follow-up throughout the trial. Radiation oncologist Dr Esther Sim, one of the study’s Principal Investigators, shared her perspective:
One exciting area in cancer treatment is antibody drug conjugates (ADCs). These are targeted therapies that combine monoclonal antibodies with powerful anticancer drugs. They’re designed to deliver treatment directly to cancer cells that express specific antigens— like HER2—while limiting damage to healthy cells. Because of their potential, ADCs have become a fast-growing area of research, with many new therapies being developed and approved over the past decade. One of these studies is the Dynasty 02 trial, a phase III clinical study for people with HER2 low, hormone receptor–positive metastatic breast cancer. Participants are randomly assigned either to the investigational ADC or to one of several standard chemotherapy options, including capecitabine, paclitaxel, or nabpaclitaxel. Study Investigator and medical oncologist Dr Nick Murray shares his thoughts on the trial:
GenesisCare’s clinical research team is currently running 21 active radiation oncology trials, reflecting our strong and ongoing commitment to advancing cancer care. Radiation therapy remains a major focus because these studies are critical to identifying safer and more effective treatments, improving survival and quality-of-life, and driving innovation in technology and care delivery. With one of the most extensive radiation oncology networks spanning metropolitan and regional locations, GenesisCare is committed to making clinical trials accessible to patients regardless of where they live. A strong example of this commitment is our involvement in the Breast Cancer Trials EXPERT trial. This phase III study investigated whether women with low-risk, early-stage luminal A
With over 93 active medical oncology trials, it is evident our GenesisCare Research and Leadership teams are dedicated to providing quality clinical research to the Australian community. Breast cancer remains an important area of research. It was the second most commonly diagnosed cancer in Australia in 2021 and is expected to stay in that position for a number of years. In 2021, more than 19,000 Australians were diagnosed with breast cancer, and that number is estimated to rise to just over 20,000 in 2025. 10 Medical oncologist Dr Nick Murray specialises in breast cancer and believes strongly in giving patients access to new treatments through clinical trials. Based at GenesisCare in Adelaide, he leads several trials as a Principal Investigator.
We have valued the opportunity to be one of the highest-enrolling contributors to this important research, which aims to improve treatment outcomes for women with early breast cancer. Personalising radiation treatment allows us to enhance quality-of-life by reducing long-term toxicities while preserving treatment effectiveness.
This trial offers an important opportunity for patients whose
cancer has progressed after standard treatments. It provides access to a therapy that isn’t otherwise available. If the investigational ADC proves to be more effective or easier to tolerate than current chemotherapy options, it could lead to better outcomes for future patients.
93
12 Research projects /registries
14 Research sites 4 Publications and presentations
21
11 Research projects /registries
55
20
41
Clinical trials
Investigators
Clinical trials
Publications and presentaions
Investigators
43
65
16
724
Top disease sites Prostate, Breast, Basket
Prostate, Lung, Breast Top disease sites
3262
External sponsors
Research sites
Patients in trials
External sponsors
Patients in trials
18
19
Theranostics
Haematology
lymphoma and rituxumab for marginal zone lymphoma. Zanubrutinib works by blocking the B-cell lymphoma-2 (Bcl-2) protein and blocks the
clinical trial—is available across multiple GenesisCare sites. It compares the targeted therapy TLX591-Tx, in combination with standard care, against standard care alone. The study, sponsored by Telix Pharmaceuticals, is investigating a new treatment approach for men with advanced, PSMA positive metastatic prostate cancer that has not responded to prior therapies. The therapy uses the antibody rosopatamab, which targets PSMA expressing cancer cells and is linked to the radioactive isotope lutetium177, potentially enabling precise delivery of radiation directly to tumour sites. Study Investigator and Nuclear Medicine Physician Dr Aviral Singh shared his perspective on the trial:
Bruton tyrosine kinase (BTK) protein. The rationale for the combination of
zanubrutinib with an anti-CD20 inhibitor is to evaluate whether this will result in a favourable benefit-risk profile and to see if by targeting lymphoma cells in multiple ways is more effective than using one drug alone. The primary endpoint for this study is progression free survival (PFS). Study Investigator, haematologist, Dr Wilf Jaksic had this to say about the study:
2025 has been a year of significant progress in Theranostics, with the Australian oncology clinical trials landscape enabling access to early-phase studies of innovative targeted radionuclide therapies. Our GenesisCare Theranostics team has been at the forefront of this growth, expanding both research and site capabilities and establishing a strong reputation as a leading global provider of Theranostics clinical trials. As a result, GenesisCare has now contributed to more than 37 Theranostics studies. The team is currently managing 13 active studies, three in follow-up, and eight in startup across our network. GenesisCare is committed to ensuring men with prostate cancer have access to new treatment options, with several trials currently open to recruitment. Prostate cancer was the most commonly diagnosed cancer in 2021 and is projected to remain so through 2025. 11 The ProstACT Global trial—a phase III randomised
GenesisCare continues to expand its haematology clinical trial portfolio, with increasing numbers of studies and participating sites throughout 2025. We currently have 8 active haematology studies, with additional trials in the pipeline. Our growing haematology clinical trials program, supported by an expanding suite of Principal Investigators, ensures GenesisCare clinical research remains at the forefront of blood cancer innovation. Our GenesisCare, North Adelaide team is currently working with Principal Investigator, haematologist Dr Wilf Jaksic on a phase 3 clinical trial for relapsed/refractory follicular and marginal zone lymphoma. The BGB-3111- 308 (Mahogany) study is sponsored by BeOne Medicines. The purpose is to compare the effectiveness of the investigational drug zanubrutinib in combination with obinutuzumab for follicular
We were grateful to be able to participate in the Mahogony BGB- 3111-308 study of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab in patients with relapsed/ refractory follicular lymphoma at GenesisCare, North Adelaide. The need for effective and tolerable second-line or later alternative regimens to current immunochemotherapy is potentially addressed with this study.
The study aims to evaluate the safety and potential benefits of PSMA based Theranostics— particularly its ability to improve survival and quality-of-life for patients with advanced disease. This targeted approach may offer a safer and more personalised treatment option and I’m proud to lead this international effort from Perth.
4
8
0 Research projects /registries
0 Publications and presentations
9
17
1 Research projects /registries
2 Publications and presentations
Clinical trials
Investigators
Clinical trials
Investigators
3
8
8
11
31
8
Breast, Lung, Prostate Top disease sites
Lymphoma
Patients in research
Top disease sites
External sponsors
Research sites
Patients in trials
External sponsors
Research sites
20
21
Benign - DEPART trial
2025 has been a landmark year for benign conditions within our radiation oncology research portfolio. The DEPART randomised trial for patients with Dupuytrens’ Disease (DD) is a flagship example of our commitment to innovation and patient-centred care in this area. We are proud to partner internationally with colleagues at the University Medical Center Gronigen in the Netherlands who have contributed significantly to the recruitment and follow-up of patients in DEPART. This international collaboration is a first for a GenesisCare investigator-initiated trial. This year, DEPART achieved significant recognition, with our paper on interim acute toxicity and quality-of-life outcomes accepted by the prestigious Red Journal, and the results presented by Prof Jarad Martin at the ASTRO Annual Meeting in San Francisco. Key findings • Low dose radiation therapy (LDRT) for DD is well-tolerated with minimal ongoing toxicities • Quality-of-life (QOL) is possibly improved by LDRT
Adverse events after adjuvant radiation therapy for Dupuytren’s disease in the DEPART randomized trial - Tanya Burgess, Eric Wegener, Brett McClelland, David Hunter-Smith, Paul M.N. Werker, Jarad Martin, , DEPART Clinical Trial Collaboration, DEPART Clinical Trial Collaboration, 2025 Prof Jarad Martin was also privileged to present the Presidential Symposium at ASTRO in 2025, highlighting the expertise he and GenesisCare offer in this area. This milestone reflects the dedication of our multidisciplinary team, whose efforts are contributing to advancing the understanding of radiation therapy for non-malignant conditions. Our collaborative approach has enabled us to deliver high-quality evidence that informs best practice, ensuring that patients with non-malignant diseases receive care that is both effective and minimally disruptive to their daily lives. Looking ahead, we are excited to extend the reach of the DEPART trial by onboarding highly regarded international colleagues. Prof Jarad Martin has been actively fostering global partnerships, aiming to collaborate with exceptional clinicians and researchers from the USA and Canada to strengthen recruitment to the adjuvant cohort of the study. These international collaborations will enrich our trial with diverse expertise and perspectives, ultimately benefiting patients worldwide. In addition to the DEPART trial, we plan to launch the PROSPECT OA registry study in early 2026, which will focus on prospective data collection using radiation therapy to treat osteoarthritis. This initiative further demonstrates our commitment to expanding research and treatment in non-malignant conditions and leveraging research as a foundation for future growth and collaboration. Together, with our local and international partners, we are shaping the future of radiation oncology for non-malignant diseases, delivering hope, improving outcomes, and setting new standards in care.
• Follow-up ongoing to assess longer term toxicities, QOL and impact on disease control
If you would like to read the full article, you can access it here: Full text: Toxicities and Quality of Life following Observation or Radiation Therapy for Dupuytren’s disease (Red Journal) redjournal.org. This paper also won the Chris Atkinson Prize for best proffered Radiation Oncology paper at the 2025 RANZCR ASM. Another DEPART publication focusing on toxicity following adjuvant RT was published this year in the Sage and Journal of Hand Surgery (European Volume).
Prof Jarad Martin presenting at ASTRO, 2025
22
23
MR-Linac program
Verification of high treatment quality across cancer sites Over the past year, our MR-Linac teams have undertaken extensive reviews of patient outcomes across multiple cancer sites. One study focused on men who had undergone prostate surgery and later required radiation therapy. Forty-seven patients were treated using MR-guided adaptive radiation therapy, with some also receiving a targeted radiation boost enabled by advanced imaging. The review showed that treatment was safe and well tolerated, with generally mild, temporary side effects. Importantly, the targeted boost did not increase complication rates, and prostate-specific antigen (PSA) levels dropped significantly in most patients, an indicator of good disease control. 12 A second project evaluated patients receiving stereotactic radiation therapy for prostate cancer, a highly precise, short-course treatment. Clinicians were able to safely deliver escalate doses to the primary target while protecting surrounding organs. Side effects were again generally mild, and PSA reductions indicate a robust treatment response.
MR-Linac teams contribute to advancing imaging innovation in radiation therapy
Subsequent investigation by our teams measured the apparent diffusion coefficient in prostate patients. This study 15 showed a measurable change between the start and end of treatment, indicating biological response to radiation therapy. These early findings move us closer to future treatment pathways informed by individual bio-sensitivity.
Outcome evaluations also extended to pancreatic cancer. Findings confirmed that MR-guided adaptive radiation therapy can be delivered safely, achieving target doses while keeping toxicity low. These results highlight evolving improvements in radiation therapy delivering meaningful progress in treatment areas previously constrained by toxicity limitations. 13 Collectively, these results demonstrate the ability to deliver personalised, targeted and well-tolerated MR-guided radiation therapy. GenesisCare joins the international phase III trial, ULTRAS The MR-linac teams in Sydney and Perth are pleased to have opened the ULTRAS international phase III clinical trial this year. ULTRAS is evaluating treatment of liver metastases on MR-Linac systems in a single, high-dose treatment session. Building on promising outcomes from a previous phase II study, this trial will assess the safety and efficacy of this innovative approach across multiple centres internationally.
The integration of MR imaging during treatment in MR-Linac systems allows access to sophisticated imaging techniques that have been found to be diagnostically important in recent years. One such technique – diffusion- weighted imaging – measures a biological property of tissue, the apparent diffusion coefficient (ADC), a biomarker reflecting tissue microstructure and cancer-related changes. In a study published this year 14 , our researchers measured the apparent diffusion coefficient using three MR-Linac systems across Australia. Both models and a healthy volunteer were scanned to test accuracy and consistency across sites. Results showed that most measurements met international quality standards, with excellent repeatability in controlled model tests and acceptable variability in patient imaging. These findings confirm that MR-Linac systems can generate high quality imaging biomarkers, without increasing burden for patients. Establishing this reliability paves the way for large, multi- centre clinical trials that use MRI biomarkers to personalise cancer care.
Streamlining prostate radiation therapy
Stereotactic treatment for prostate cancer can currently be offered as a course of five treatment sessions, but emerging evidence suggests that giving the same treatment in just two sessions may be feasible. Our team modelled how adaptive MR‑guided radiation therapy could safely deliver this ultra-short course treatment. The simulations showed that MR‑guided radiation therapy could deliver high doses to the tumour while keeping doses to surrounding organs within safe limits. These findings suggest that ultra‑short, two‑session prostate radiation therapy could be delivered safely with MR‑guided radiation therapy systems. This work paves the way for GenesisCare to join the DESTINATION-2 international clinical trial which will evaluate clinical delivery of the two-session approach.
WA ULTRAS team following successful enrolment of the first patient
MR-Linac team successes at CINSW Cancer Summit Conference, 2025
24
25
Quality
These experiences provided Robyn with a valuable introduction into the current landscape in both the research/healthcare sector overall and within GenesisCare that will enable her to contribute her valuable insights to our Consumer Engagement Strategy moving forward. Additional quality improvement initiatives have included the implementation of a digital Clinical Trial Management System (CTMS). This represents a significant step forward in digital transformation of our clinical research operations. The CTMS is a relational database that enables structured, standardised, and efficient capture of clinical trial activity and performance data across the research lifecycle, improving the quality, timeliness, and reliability of information used for oversight, decision- making, and reporting. In conjunction with our electronic Investigator Site File (eISF)/ digital document management system we’ve achieved further reduction in manual handling and increased operational efficiency while strengthening data reliability.
These capabilities directly support the National Clinical Trials Governance Framework by enhancing organisational oversight, risk management, and accountability for clinical trial activity. The CTMS enables routine, near- real-time monitoring of key governance and quality indicators, including trial portfolio composition, feasibility and start-up timelines, ethics and governance approval durations, participant recruitment and retention performance, protocol deviations and serious breach reporting, safety reporting timeliness and study close-out performance. The availability of high-quality, aggregated data through the CTMS improves the efficacy of governance processes by enabling early identification of emerging risks, targeted quality improvement activities, and evidence- based resource planning. Collectively, these digital systems strengthen alignment with NCTGF principles by enabling transparent internal reporting to our leadership committees and board, and to external oversight bodies such as ethics committees, sponsors, and regulators.
In 2025, Health Service Accreditation SNAP assessments continued across multiple jurisdictions, with inspections undertaken in Queensland and Victoria. Building on assessments completed in South Australia, New South Wales, and Western Australia in 2024, our Clinical Trials program was assessed against the 27 action items outlined in the National Clinical Trials Governance Framework, completing our accreditation cycle across all our state-based services. These assessments are conducted under the authority of the Australian Commission on Safety and Quality in Health Care and form part of the National Safety and Quality Health Service (NSQHS) accreditation program. They play a vital role in reinforcing the quality, safety, and governance of the clinical trials available to our patients. The assessments confirmed a high level of alignment with the National Clinical Trials Governance Framework, recognising robust operational systems while identifying targeted opportunities for continuous improvement. At GenesisCare, we are committed to partnering with patients in everything we do. In 2025, we strengthened this commitment by working towards the goal of embedding consumer engagement across the research lifecycle, in alignment with the National Clinical Trials Governance Framework. We continued with existing avenues of consumer engagement including but not limited to: • Providing information about clinical trials and research at GenesisCare via the website • Ensuring review of patient facing trial information by consumer representatives so that the information is easy to understand • Disseminating lay summaries of results of trials to participants • Disseminating information about clinical trials to the community via social media and other media releases
These foundations were built upon by: • Establishing a presence with the GenesisCare Consumer Advisory Committee (CAC) to report on research activities and seek advice • Developing a draft Consumer Engagement Strategy (2025-2027) to create a roadmap for embedding engagement • Recruiting consumer representatives from the CAC to join a research subcommittee that will oversee further
development and execution of the Consumer Engagement Strategy.
These initiatives will enhance transparency, trust, and relevance in clinical research, ensuring that consumer voices shape trial design and delivery. The groundwork laid in 2025 positions GenesisCare to achieve full integration and sustainability of consumer engagement practices in the coming years.
Improving capacity for consumers to partner with research
The research team was thrilled to have Robyn Hughes, a valued member of the GenesisCare Consumer Advisory Committee (CAC), volunteer to join us as a consumer representative for research. A critical component in supporting consumer partnership in research in capacity building, which was a key priority in the initial stages of working together. Robyn was awarded a consumer scholarship to attend the ACTA Clinical Trials and Registries Symposium in Melbourne, supported by the research team. The symposium, hosted by the Australian Clinical Trials Alliance, focussed on advancing a self-improving healthcare system through the design and conduct of clinical trials, registries, health data, policy, regulation, and patient advocacy. Robyn also visited one of our centres, meeting the research team and seeing what research at GenesisCare looks like first-hand.
Robyn Hughes (centre) with members of the GenesisCare Victoria Research team
26
27
Partnerships
Participation in the Perkins Partners Program enhances opportunities for collaborative research, clinical trials and the acceleration of novel therapies into routine patient care. GenesisCare further strengthened its role in the rapidly evolving field of Theranostics through collaboration with the National Imaging Facility (NIF) at the Harry Perkins Institute , supporting advanced imaging and Theranostics focused clinical trials. In addition, GenesisCare partnered with industry collaborators Cyclowest and Quantam to support Theranostics studies that leverage specialised radiopharmaceutical manufacturing and radio-labelling capabilities. Together, these collaborations position GenesisCare at the forefront of precision oncology and reinforce its commitment to research-driven, patient-centred care. In parallel, GenesisCare continued to invest in research capacity building and workforce development. In partnership with UNSW , GenesisCare is supporting a physics PhD student over a three-year program. The student’s research focuses on the application of deep learning techniques using largescale
In 2025, GenesisCare continued to build on its strong foundation of strategic partnerships, recognising collaboration as a critical driver of research excellence and innovation in cancer care. Through sustained engagement with leading Australian universities, including the University of Sydney, the University of New South Wales (UNSW) and Edith Cowan University, as well as local health districts and research organisations , GenesisCare actively contributed to and collaborated on a growing portfolio of externally led research projects. These partnerships strengthen translational research and support the rapid integration of evidence-based advances into clinical practice. A key milestone during the year was GenesisCare’s inclusion in the Perkins Partners Program at the Harry Perkins Institute of Medical Research. This partnership aims to bring together cutting- edge research and worldclass specialised healthcare, closely aligning with GenesisCare’s established leadership in radiation therapy and its expanding footprint in medical oncology, theranostics and personalised medicine.
clinical data, combining GenesisCare datasets with broader data from the Australian Clinical Cancer Data Network . This collaboration exemplifies GenesisCare’s commitment to advancing data-driven innovation in oncology and fostering the next generation of clinician-scientists and researchers. GenesisCare continues to work closely with Cancer Australia to embed and strengthen our existing partnership to implement the Australian Cancer Plan, building on a shared commitment to improving cancer outcomes through collaboration, evidence-based policy, and system-wide impact. Through ongoing engagement under the Partnership Agreement, GenesisCare is supporting national efforts to advance cancer control priorities, contribute clinical expertise and insights from service delivery, and help translate research and policy into meaningful improvements for patients. This work reflects a mutual focus on strengthening coordination across the cancer ecosystem and ensuring that innovation, access, and quality remain central to Australia’s cancer response.
Moving forward into 2026, we are formalising partnerships with both Omico and Rare Cancers Australia (RCA) . Both GenesisCare and Omico share a commitment to expanding access to precision oncology and improving outcomes for patients with complex and advanced cancers. The proposed collaboration will increase referrals to Omico for comprehensive genomic profiling and treatment matching for patients with incurable cancer, strengthen the use of data to inform treatment and follow-up, and improve access to and coordination of clinical trials across geographies. These efforts will also support precision oncology becoming standard of care. The proposed partnership with RCA will reflect a shared commitment to improving outcomes and access to specialised support for people diagnosed with rare and less common cancers which affect around one in four Australians diagnosed with cancer and account for more than a third of cancer-related deaths nationally. Through this collaboration, GenesisCare and RCA will work together to enhance patient access to information, expertise and therapies.
Pictured left to right: Exercise oncology researcher: Mary Kennedy, Clinical Director Theranostics: A/Prof Joe Cardaci, Radiation Oncologist, Medical Director GenesisCare WA: A/Prof Yvonne Zissiadis, Prof Peter Leedman AO, Perkins Corporate Engagement Partner: Celia Byatt, Radiation Oncologist: A/Prof Raphael Chee, Nuclear Medicine and Theranostics Lead: Tiffany Briggs
Rare Cancers Australia Canforum25 (L-R: CEO, GenesisCare Australia: Richard Lizzio, CEO, RCA: Christine Cockburn, Head of Government Affairs: Natalie Cope, Head of Partnerships, RCA: Nikki Kerr)
28
29
Sponsorships and events
In 2025, GenesisCare was a proud sponsor at multiple industry events where our esteemed research team had the opportunity to present key findings, learn and connect with industry peers. These events include:
• Australasia Skin Cancer Congress
• TOGA ASM
• NSW Cancer Summit
• Asia-Pacific Prostate Cancer Conference (APCC), with the sponsorship of the Radiation Oncology session • Australian and New Zealand Head and Neck Cancer Society’s Annual Scientific Meeting (ANZHNCS ASM) • Australian Society for Breast Disease (ASBD) ASM - 14th Scientific Meeting • RANZCR ASM featuring a number of presentations from GenesisCare doctors and staff, and sponsorship of international speaker Prof Amar Kishan • HealthEd webinar, A/Prof Yvonne Zissiadis presented on innovations in Breast Radiation
NSW Cancer Summit (L-R: Amanda Woods, Hilary Byrne, Valery Peng)
NSW Cancer Summit (L-R: Jane Lynch, Amanda Woods, Courtney Leslie, Hilary Byrne, Samantha Redfearn)
• Rare Cancers Long Lunch
• Sonya McColl, Head of Research, attended the Health Industry Hub Awards • Clinical Oncology Society of Australia (COSA) Adelaide - A/Prof Yvonne Zissiadis shared insights on integrating a patient navigation program for breast cancer into cancer care.
COSA Adelaide (A/Prof Yvonne Zissiadis)
Asia Pacific Prostate Cancer Conference (APCC) (L-R: Dr Cristian Udovicich, Dr Marcus Foo, Dr Mario Guerrieri, Dr Jeremy de Leon)
30
31
L-R Justin’s wife, Justin, Amber
JT’s Journey: A Life-Saving Experience
All in a Day’s Work: Amber’s Story
When Amber Quan returned from maternity leave, she was eager to dive back into her role as a Clinical Research Coordinator. One of her first projects on return was a new Theranostics study. Amber set herself a personal challenge: find the right patient for this trial. She started by reviewing the pre-screening log—a tool the team uses to track potential Theranostics patients. That’s when she spotted a familiar name: a patient who had shown interest in a trial the previous year but hadn’t been successful. Amber reached out, and to her delight, he was keen to learn more about the clinical trial. From there, Amber connected with the Principal Investigator and after review and screening, the patient was eligible and booked for his first dose. Amber didn’t stop there. She coordinated everything for treatment day—ordering the investigational product, liaising with departments, and ensuring all hands were on deck.
When JT talks about his experience, his words are simple but powerful: “Good to know all clear. All pain has disappeared.” For him, those words mean everything. JT is a 66-year-old country man who first learned he had prostate cancer back in 2016. At the time, it was low-risk, so he went on active surveillance and carried on with life. But in 2025, things changed—a new biopsy showed his cancer had become more aggressive, and his PSA level was rising. That’s when JT qualified for the NINJA clinical trial, and he didn’t hesitate. “I wanted to get this sorted and get back home,” he recalls. His journey began with pain in his left testicle, which led him to Royal Perth Hospital. Surgery wasn’t an option there, so he was referred to A/Prof Tee Lim at Fiona Stanley Hospital (FSH). On August 12, 2025, JT enrolled in the trial and started radiation therapy.“For me, the relief was immediate, it changed everything for me”, JT says.
Thanks to her meticulous planning, the patient received his treatment smoothly and according to protocol. For Amber, it was a proud moment—made even sweeter because it happened on her son’s birthday! Reflecting on the experience, Amber shared: I don’t think the day would have happened for this patient if I didn’t go back and look through the log, so I am proud that he is on trial now. This milestone wasn’t just a win for Amber. It was a triumph for the patient, the doctor, the sponsor, and the entire team. Behind every successful trial is a network of effort—from feasibility checks and ethics approvals to site readiness and day-to-day coordination. Amber’s story is a shining example of the dedication that makes it all possible. Stories like Amber’s remind us that every detail matters—and every effort brings us closer to improving lives.
Speed mattered to JT. Living in the country, he didn’t want to be away from home for long. Thanks to the team at FSH, his treatment was quick and effective. He stayed at Millroy Lodge, a Cancer Council facility for regional patients, and couldn’t stop praising their hospitality. “They were fantastic,” he says. Even better, he ran into friends during his stay, which made the experience feel less isolating. Family is everything to JT. Married with three children, he even encouraged his younger brother to get checked. “Don’t wait,” he told him. “It’s worth it.” JT’s story is a reminder of what timely care and compassionate support can achieve. For him, the NINJA trial wasn’t just treatment—it was a chance to keep living life on his terms.
The NINJA clinical trial aims to compare two emerging schedules of radiation therapy in the treatment of intermediate or high-risk prostate cancer.
32
33
Page 1 Page 2-3 Page 4-5 Page 6-7 Page 8-9 Page 10-11 Page 12-13 Page 14-15 Page 16-17 Page 18-19 Page 20-21 Page 22-23 Page 24-25 Page 26-27 Page 28-29 Page 30-31 Page 32-33 Page 34-35 Page 36-37 Page 38-39 Page 40-41 Page 42-43 Page 44-45 Page 46-47 Page 48-49 Page 50-51 Page 52Made with FlippingBook Annual report maker